Physician profile
Kevin E Dehart
NPI 1528256872
$25,602.13
in general payments reported to CMS, 2019-2025
34 companies · $4,722 in 2025
The $4,722 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,995 · 2020: $1,800 · 2021: $2,024 · 2022: $4,138 · 2023: $1,863 · 2024: $2,060 · 2025: $4,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,918 · Honoraria: $2,750 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $873 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,917.67 |
| Honoraria | $2,750.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $872.81 |
| Education | $104.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $8,208.96 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $3,623.95 | 2019-2025 | Skyrizi, Rinvoq |
| Lnhc, INC | $2,884.26 | 2025 | Zelsuvmi |
| Galderma Laboratories, L.P. | $2,302.13 | 2019-2025 | Epsolay, Nemluvio |
| Genzyme Corporation | $895.88 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $842.57 | 2019-2025 | |
| Leo Pharma INC. | $840.25 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $757.12 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $730.16 | 2019-2025 | Blu-U, Odomzo |
| Pfizer INC. | $652.98 | 2019-2025 | |
| Amgen INC. | $560.00 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $482.63 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $480.37 | 2019-2024 | Dupixent |
| Lilly USA, LLC | $396.75 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $332.58 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $309.07 | 2022-2025 | Sotyktu |
| Biofrontera INC. | $285.43 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Incyte Corporation | $149.01 | 2021-2025 | Opzelura |
| Epi Health, LLC | $147.59 | 2020-2021 | |
| Botanix Sb INC | $144.67 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $102.99 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $102.30 | 2019-2021 | |
| Genentech USA, INC. | $59.40 | 2019-2021 | |
| Aclaris Therapeutics, INC. | $58.32 | 2019 | |
| Strata Skin Sciences, INC. | $43.08 | 2019-2021 | |
| Dermira, INC. | $36.43 | 2019-2020 | |
| Organon LLC | $29.73 | 2025 | Vtama |
| Springworks Therapeutics, INC. | $27.96 | 2025 | Gomekli |
| Verrica Pharmaceuticals INC. | $24.10 | 2023 | Ycanth |
| Kyowa Kirin, INC. | $23.60 | 2024 | Poteligeo |
| Celgene Corporation | $21.80 | 2019 | |
| Dusa Pharmaceuticals, INC. | $20.60 | 2019 | |
| Convatec INC. | $13.32 | 2024 | |
| Hill Dermaceuticals, INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Dehart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.